Terms: = Thyroid cancer AND TERT, EST2, Q8NG46, Q8N6C3, Q2XS35, O14783, O14746, 7015, hEST2, TCS1, TRT, TP2 AND Clinical Outcome
16 results:
1. Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and tert promoter alterations favour malignant struma ovarii.
Neyrand S; Trecourt A; Lopez J; Just PA; Descotes F; Borson-Chazot F; Ray-Coquard I; Decaussin-Petrucci M; Devouassoux-Shisheboran M
Histopathology; 2024 Jan; 84(2):291-300. PubMed ID: 37771077
[TBL] [Abstract] [Full Text] [Related]
2. Approach to risk stratification for papillary thyroid carcinoma based on molecular profiling: institutional analysis.
Staubitz JI; Müller C; Heymans A; Merten C; Roos B; Poplawski A; Ludt A; Strobl S; Springer E; Schad A; Roth W; Musholt TJ; Hartmann N
BJS Open; 2023 May; 7(3):. PubMed ID: 37146205
[TBL] [Abstract] [Full Text] [Related]
3. The role of the size in thyroid cancer risk stratification.
Vianello F; Censi S; Watutantrige-Fernando S; Barollo S; Zhu YH; Albiger N; Bertazza L; Manso J; Carducci S; Benna C; Iacobone M; Galuppini F; Pennelli G; Mian C
Sci Rep; 2021 Mar; 11(1):7303. PubMed ID: 33790328
[TBL] [Abstract] [Full Text] [Related]
4. Spatial Distribution Patterns of clinically Relevant tert Promoter Mutations in Follicular thyroid Tumors of Uncertain Malignant Potential: Advantages of the Digital Droplet PCR Technique.
Hysek M; Jatta K; Hellgren LS; Stenman A; Larsson C; Zedenius J; Juhlin CC
J Mol Diagn; 2021 Feb; 23(2):212-222. PubMed ID: 33197629
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic value of
van Ipenburg JA; Naus NC; Dubbink HJ; van Ginderdeuren R; Missotten GS; Paridaens D; Verdijk RM
Br J Ophthalmol; 2021 Oct; 105(10):1454-1461. PubMed ID: 33127831
[TBL] [Abstract] [Full Text] [Related]
6. Molecular characterisation and clinical correlation of papillary thyroid microcarcinoma.
Samà MT; Grosso E; Mele C; Laurora S; Monzeglio O; Marzullo P; Boldorini R; Aluffi Valletti P; Aimaretti G; Scatolini M; Pagano L
Endocrine; 2021 Jan; 71(1):149-157. PubMed ID: 32621051
[TBL] [Abstract] [Full Text] [Related]
7. HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic thyroid cancer Cell Line.
Hegedűs L; Rittler D; Garay T; Stockhammer P; Kovács I; Döme B; Theurer S; Hager T; Herold T; Kalbourtzis S; Bankfalvi A; Schmid KW; Führer D; Aigner C; Hegedűs B
Pathol Oncol Res; 2020 Oct; 26(4):2523-2535. PubMed ID: 32591993
[TBL] [Abstract] [Full Text] [Related]
8. GADD45B Transcript Is a Prognostic Marker in Papillary thyroid Carcinoma Patients Treated With Total thyroidectomy and Radioiodine Therapy.
Barros-Filho MC; de Mello JBH; Marchi FA; Pinto CAL; da Silva IC; Damasceno PKF; Soares MBP; Kowalski LP; Rogatto SR
Front Endocrinol (Lausanne); 2020; 11():269. PubMed ID: 32425887
[TBL] [Abstract] [Full Text] [Related]
9. Tall Cell Variant of Papillary thyroid Carcinoma: Impact of Change in WHO Definition and Molecular Analysis.
Wong KS; Higgins SE; Marqusee E; Nehs MA; Angell T; Barletta JA
Endocr Pathol; 2019 Mar; 30(1):43-48. PubMed ID: 30565013
[TBL] [Abstract] [Full Text] [Related]
10. Genetic landscape of papillary thyroid carcinoma in the Chinese population.
Liang J; Cai W; Feng D; Teng H; Mao F; Jiang Y; Hu S; Li X; Zhang Y; Liu B; Sun ZS
J Pathol; 2018 Feb; 244(2):215-226. PubMed ID: 29144541
[TBL] [Abstract] [Full Text] [Related]
11. Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer.
Tesselaar MH; Smit JW; Nagarajah J; Netea-Maier RT; Plantinga TS
J Mol Endocrinol; 2017 Nov; 59(4):R141-R154. PubMed ID: 28931558
[TBL] [Abstract] [Full Text] [Related]
12. Application of molecular biology of differentiated thyroid cancer for clinical prognostication.
Marotta V; Sciammarella C; Colao A; Faggiano A
Endocr Relat Cancer; 2016 Nov; 23(11):R499-R515. PubMed ID: 27578827
[TBL] [Abstract] [Full Text] [Related]
13. Clinicopathological significance of tert promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis.
Yin DT; Yu K; Lu RQ; Li X; Xu J; Lei M; Li H; Wang Y; Liu Z
Clin Endocrinol (Oxf); 2016 Aug; 85(2):299-305. PubMed ID: 26732020
[TBL] [Abstract] [Full Text] [Related]
14. Uncommon tert Promoter Mutations in Pediatric thyroid cancer.
Alzahrani AS; Qasem E; Murugan AK; Al-Hindi HN; AlKhafaji D; Almohanna M; Xing M; Alhomaidah D; AlSwailem M
Thyroid; 2016 Feb; 26(2):235-41. PubMed ID: 26711586
[TBL] [Abstract] [Full Text] [Related]
15. tert Promoter Mutations in Papillary thyroid Microcarcinomas.
de Biase D; Gandolfi G; Ragazzi M; Eszlinger M; Sancisi V; Gugnoni M; Visani M; Pession A; Casadei G; Durante C; Costante G; Bruno R; Torlontano M; Paschke R; Filetti S; Piana S; Frasoldati A; Tallini G; Ciarrocchi A
Thyroid; 2015 Sep; 25(9):1013-9. PubMed ID: 26148423
[TBL] [Abstract] [Full Text] [Related]
16. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and tert.
Dettmer MS; Schmitt A; Steinert H; Capper D; Moch H; Komminoth P; Perren A
Endocr Relat Cancer; 2015 Jun; 22(3):419-29. PubMed ID: 25870252
[TBL] [Abstract] [Full Text] [Related]
